Clinical Trial Update: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lonafarnib/ritonavir with and without pegylated interferon alfa-2a for hepatitis delta virus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis Delta Virus

Drugs mentioned

• Lonafarnib/ritonavir with and without pegylated interferon alfa-2a

Snippet

Sponsor: Eiger BioPharmaceuticals | Conditions: Hepatitis Delta Virus | Phase 3 | Status: COMPLETED